HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal
Yahoo Finance · Sep 3, 2026 · HCM (HCM)
Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares jumped 17% to 210p on Thursday after the oncology specialist struck a licensing agreement with GSK worth up to US$1.295 billion for its experimental KRAS-EGFR cancer therapy. HUTCHMED will receive US$110 million upfront and...
Not investment advice. Cached headline, not a full reprint.